August 7, 2014 / 5:46 AM / 3 years ago

Novo Nordisk results in line with expectations, keeps outlook

COPENHAGEN, Aug 7 (Reuters) - Denmark's Novo Nordisk , the world's top maker of insulin, posted on Thursday second-quarter operating profit in line with forecasts and maintained its operating profit and sales growth outlook.

Novo Nordisk posted a quarterly operating profit of 8.73 billion Danish crowns($1.57 billion), compared to expectations of 8.56 billion crowns, on revenues of 21.63 billion crowns against forecasts of 21.7 billion crowns.

The company kept its forecast for 2014 sales growth of 7 to 10 percent and operating profit growth at around 10 percent, both in local currencies. (1 US dollar = 5.5691 Danish crown) (Reporting by Copenhagen bureau; editing by Sabina Zawadzki)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below